All In Biotech

Drug Trial Radar · NCT04592315

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Jan 23, 2021

Primary completion

May 2, 2023

Study completion Jul 11, 2023

Sponsor

Sponsor type
Industry
Collaborators
Institute of Pathogen Biology, Beijing, China
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability of single dose lipovirtide injection in HIV-infected individuals without prior antiviral treatment, and to investigate the pharmacokinetic characteristics of infected patients.

Conditions

  • HIV Infections

Interventions

  • Lipovirtide InjectionDrug

    Single dosage of Lipovirtide Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Related Adverse Events as Assessed by DAIDS v1.0Time frame: Day 1 to Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing You'an Hospital, Beijing Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.